News

Agrospheres Completes Expansion of $25 Million Series B Round

AgroSpheres, a biotechnology company pioneering breakthroughs in sustainable crop protection, today announced the closing of its Series B funding round with a strategic investment from FMC Corporation (NYSE: FMC), a global leader in agriculture sciences. This investment brings the total funding in AgroSpheres’ Series B round to $25 million, demonstrating the strong confidence in the company’s innovative solutions. FMC Ventures joins Lewis and Clark AgriFood, Ospraie Ag Science, BIDRA Ventures, and Cavallo Ventures to close out the round.

AgroSpheres has developed cutting-edge technology that enables precise delivery of active ingredients such as small molecules, peptides, and nucleic acids in crop protection products. This technology has the potential to revolutionize the agriculture industry by improving the efficiency, efficacy, and sustainability of crop protection practices.

“We are excited to invest and partner with AgroSpheres, sharing a common vision for advancing agriculture,” said Mark Brooks, managing director, FMC Ventures. “Their innovative technology has the potential to be a game changer in crop protection. With broad IP protection, manufacturing capabilities, and a strong industry network, AgroSpheres stands out in AgTech. We believe this investment will drive innovation and accelerate the development of sustainable solutions for farmers globally.”

AgroSpheres’ Co-Founder and CEO, Payam Pourtaheri, also commented on the investment, saying, “We are honored to welcome FMC Corporation as a strategic investor in AgroSpheres. Their extensive expertise in agricultural sciences and global reach make them an ideal partner for us. This investment will further empower us to continue our mission of providing more effective and sustainable solutions for the agricultural industry. Together with FMC, we will strive to make a significant impact on global agriculture.”

AgroSpheres has gained recognition for its innovative approach to precision delivery of crop protection products, reducing environmental impact, and enhancing overall crop health. This latest investment will support the company in its mission to bring this technology to more markets, helping farmers worldwide address the challenges of feeding a growing global population while minimizing the environmental footprint.

Recent News

06/11/2026

Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing

Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”) today announced that it has acquired Azora Therapeutics, Inc. (“Azora”), a biopharmaceutical company developing treatments for serious inflammatory diseases. The acquisition brings Azora’s lead asset AT177, a proprietary colon‑targeted aryl hydrocarbon receptor (AhR) agonist designed to enable localized activation with limited systemic exposure, into Adial’s pipeline.

06/11/2026

Luna Labs Launches 3 Waves Venture Spinout to Commercialize Advanced Vestibular Stimulation Technology

Luna Labs today announced the launch of 3 Waves, Inc. (“3Waves”), a dual-use spinout company that was established to commercialize advanced virtual and mixed reality technologies for defense, commercial simulation, and medical applications. As part of the spinout, 3Waves and Mayo Clinic executed an exclusive license to support the development of next-generation vestibular stimulation systems

06/02/2026

TearSolutions Receives FDA Orphan Drug and Fast Track Designations for Lacripep® in Neurotrophic Keratitis and Initiates Phase 2 Clinical Trial with First Patients Dosed

TearSolutions, Inc. (“TearSolutions”), a clinical-stage biotechnology company developing novel ophthalmic therapeutics, today announced receiving Food and Drug Administration (FDA) Orphan Drug (ODD) and Fast Track Designations for Lacripep in Neurotrophic Keratitis (NK) and initiating a Phase 2 clinical trial with first patients dosed. The FDA’s ODD provides incentives, including tax credits for clinical testing and